Why Is NHS Access to Mounjaro & Wegovy Taking So Long?
You may have read that weight-management medicines are available on the NHS, only to discover that accessing them locally is more complicated.
For many people, that gap between a national announcement and an appointment feels frustrating. It can leave you unsure whether you qualify, who to contact or what support is available while you wait.
A recent parliamentary report has brought these concerns back into focus. Here, we explain the rollout, the reasons for delays and what to consider if you are exploring a private weight-management assessment.
Information checked on 3 November 2026. This article focuses on NHS England; arrangements differ across the UK.
Why are MPs calling for faster access?
On 23 October 2026, Sky News reported MPs’ concerns about the pace of the NHS Mounjaro rollout and an emerging divide between people who can afford private care and those who cannot. [1]
The Health and Social Care Committee’s report called on the government to “urgently reassess the pace of rollout of Mounjaro”. It also recommended making greater use of digital providers’ capacity. [2]
The report described fragmented pathways and geographical variation, rather than a consistent route into care. These are criticisms of how services are organised, not evidence that every NHS service provides poor support.
Does NICE approval mean you can get treatment now?
A recommendation and immediate local access are not the same thing.
NICE assesses whether a treatment represents an appropriate use of NHS resources for specified groups. NHS organisations then need the funding, trained staff and services to deliver it.
For tirzepatide, the medicine in Mounjaro, NICE agreed an exceptional phased introduction. Around 220,000 people are intended to gain access during the first three years, prioritised by clinical need.
The maximum implementation period is 12 years, but NICE recognises that this could be shortened after reviewing the early rollout. It does not mean every patient faces a 12-year waiting list. [4]
Who is prioritised for Mounjaro in England?
The broad NICE recommendation covers adults with an initial BMI of at least 35 and at least one weight-related health condition, alongside dietary and activity support. Lower BMI thresholds apply for specified ethnic backgrounds.
However, the initial primary-care rollout is narrower.
NHS England’s current guidance includes people with a BMI of at least 35 and four or more specified conditions: hypertension, abnormal blood fats, obstructive sleep apnoea, cardiovascular disease and type 2 diabetes. Ethnicity-adjusted BMI thresholds apply. [5]
Specialist weight-management services have a separate access route under the broader NICE criteria. An assessment still determines whether treatment is suitable.
Ask your GP which pathway applies locally. Eligibility is not a promise of an immediate appointment or prescription, and the primary-care rules should not be confused with all NHS access.
Is Wegovy available through the same pathway?
Not exactly. Wegovy contains semaglutide and has different NHS recommendations.
NICE recommends it within a specialist service offering multidisciplinary weight-management care, for a maximum of two years. Adults generally need at least one weight-related condition and a BMI of 35 or above. [6]
Some people with a BMI of 30–34.9 may qualify if they meet specialist referral criteria. Lower BMI thresholds apply for specified ethnic backgrounds.
Consequently, access may depend on specialist referral and service capacity. The primary-care Mounjaro rollout does not automatically provide a GP route to Wegovy.
What is slowing the rollout?
There is more involved than purchasing medicines.
Funding: NHS organisations must plan for medicine costs and the care delivered alongside them.
Workforce: Prescribers need training, time for assessment and capacity for ongoing reviews.
Support services: Dietary, activity and behavioural support must be available alongside prescribing.
Local delivery: Integrated Care Boards organise services for their populations, which can create different routes and experiences.
NHS England says phasing is intended to manage demand and build safe, sustainable services. Its guidance allows different delivery models, including general practice and community-based provision. [7]
For patients, those practical constraints can translate into uncertainty and waiting. That frustration is understandable, even when the reasons are more complicated than an individual GP’s decision.
Could private care offer a more straightforward route?
For someone who can afford it, a private assessment may be available sooner than a local NHS appointment. Remote consultations can also reduce travel and make it easier to fit care around work or family.
A clearly organised service can offer a named contact route, planned reviews and explanations about the next step. These are useful features to compare when choosing care.
However, response times, appointment availability and the level of support vary between providers. Private care is not automatically faster, safer or more comprehensive.
Private prescribing is not governed by the NHS’s phased funding cohorts, but it must still meet clinical and regulatory requirements. Paying for an assessment does not guarantee medication.
What should you check before paying?
Ask what the service actually includes:
Who assesses you, prescribes and dispenses any medicine?
How are your medical history and existing medicines checked?
How do you obtain advice about side effects or concerns?
Are follow-up reviews and nutritional support included?
What are the ongoing costs, and what happens if treatment changes?
At AJ Hill Aesthetics, the published service information explains its intermediary role between patient, prescriber and dispensing pharmacy. Information is forwarded for review by a UK-regulated prescriber; any approved prescription is dispensed through a UK-registered pharmacy. [8]
Check current service details and support arrangements before deciding. Consider affordability over time, rather than only the first month, and do not assume that starting privately guarantees a later transfer to NHS prescribing.
You deserve clear information and ongoing support
NHS services can provide valuable specialist, multidisciplinary care. Private assessment may offer another route for some people, but affordability remains a real barrier.
While exploring your options, ask your GP about local eligibility and other support available now. Nutrition, activity, behavioural programmes and, for some people, surgery may also form part of appropriate care.
The right pathway should provide an individual assessment, realistic expectations and follow-up. There should be space to discuss benefits, risks and alternatives without pressure to start treatment.
This article provides general information, not a guarantee of NHS eligibility or a recommendation for a particular prescription medicine.
